Nonsteroidal mineralocorticoid receptor antagonists (MRAs) are a new class of drugs
developed to address the medical need for effective and safer treatment to protect the kidney …

Diabetic kidney disease (DKD) represents a major public health issue, currently posing an
important burden on healthcare systems. Renin–angiotensin system (RAS) blockers are …

Chronic kidney disease (CKD) is one of the most frequent complications associated with
type 2 diabetes mellitus (T2DM) and is also an independent risk factor for cardiovascular …

Despite existing treatments, patients with heart failure and chronic kidney disease (CKD)
remain at high risk for adverse outcomes and progression to end-stage disease. Steroidal …

Chronic kidney disease (CKD) is the leading complication in type 2 diabetes (T2D) and
current therapies that limit CKD progression and the development of cardiovascular disease …

Approximately 30%–40% of patients with type 1 or type 2 diabetes (T1D/T2D) develop
diabetic kidney disease (DKD), which can lead to end-stage kidney disease (ESKD) …

Abstract Purpose of Review Novel non-steroidal mineralocorticoid receptor (MR)
antagonists (MRAs) are a new class of drugs blocking adverse MR-mediated effects with an …

Chronic kidney disease (CKD) in type 2 diabetes is a large and growing problem leading to
end-stage kidney disease, atherosclerotic cardiovascular disease, and heart failure (HF) …

The overactivation of the mineralocorticoid receptor (MR) in animal models of chronic kidney
disease (CKD) increases sodium retention, hypertension and provokes inflammation and …

This review covers the last 80 years of remarkable progress in the development of
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …